|
MechanismMALT1 inhibitors |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
The study will be conducted in 3 parts:
Part A: MPT-0118 dose-escalation
Part B: MPT-0118 dose-escalation in combination with pembrolizumab
Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
100 Clinical Results associated with Monopteros Therapeutics, Inc.
0 Patents (Medical) associated with Monopteros Therapeutics, Inc.
100 Deals associated with Monopteros Therapeutics, Inc.
100 Translational Medicine associated with Monopteros Therapeutics, Inc.